Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND IBUPROFEN versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND IBUPROFEN versus TOLECTIN 600.
HYDROCODONE BITARTRATE AND IBUPROFEN vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Hydrocodone: 3.8-4.5 hours (immediate release); Ibuprofen: 1.8-2.5 hours (racemic, S-enantiomer slightly shorter). Clinical context: dosing every 4-6 hours due to hydrocodone half-life.
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Hydrocodone: primarily renal (60-70% as metabolites, <12% unchanged); Ibuprofen: primarily renal (90% as metabolites and conjugates, <1% unchanged), minor biliary/fecal.
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category D/X
Category C
NSAID
NSAID